Antineoplastic agents may be very effective in the first round of combination chemotherapy; however, upon subsequent treatment, many tumours display resistance. In many instances, drug resistance is observed to multiple agents which differ in structure as well as in their mechanism of action. Development of such multidrug resistance (MDR) is a major obstacle in the treatment of a variety of malignancies (Kaye, 1988) . Although the altered expression of a number of proteins has been associated with MDR in different model systems, the overexpression of a 150-180 kDa glycoprotein has been the most consistent. This glycoprotein, termed Pglycoprotein, acts as an energy dependent efflux pump to reduce drug accumulation within the cell (Gerlach et al., 1986a) . While overexpression of P-glycoprotein is clearly responsible for MDR in some cell systems, it is unlikely that P-glycoprotein by itself can account for the plethora of biochemical and genetic changes which occur as a cell adapts to growth in the presence of antineoplastic agents (Kaye, 1988) . The isolation of MDR cell lines which do not overexpress P-glycoprotein, and the detection of P-glycoprotein in only a subset of patients with drug-resistant tumours (Goldstein et al., 1989) , support a multifactorial model of MDR (Mirski et al., 1987; Danks et al., 1987; Slovak et al., 1988; McGrath et al., 1989) .
A number of monoclonal antibodies have been derived with specificity for P-glycoprotein and have proven to be valuable tools in the analysis of the MDR phenotype mediated by P-glycoprotein (Kartner et al., 1985; Scheper et al., 1988; Hamada & Tsuruo, 1988a, b; Thiebaut et al., 1987) . In the present study, we report the derivation of a monoclonal antibody against a MDR human ovarian carcinoma cell line, A2780.AD (AD) (Rogan et al., 1984) , which recognises a cell surface antigen whose association with drug resistance appears independent of P-glycoprotein.
A 6-8-week-old female Balb/c mouse was immunised with four i.p. injections, each consisting of 10 x 106 viable AD cells, on days 1, 7, 17 and 35 days. Four days following an i.v. injection of 5 x 106 AD cells on day 59, the immune spleen cells were fused with P3.NSI/Ag4.1 (NS-1) myeloma cells using a 50% (w/v) polyethylene glycol solution (Kennett, 1979) . Hybrids were selected in hypoxanthine, aminopterin and thymidine-containing medium and at 10-14 days post-fusion, supernatants from wells containing macroscopically visible hybridomas were tested for specific antibodies using an indirect enzyme-linked immunosorbent assay (ELISA) with AD cells and the corresponding drug-sensitive A2780-9S (9S) cells (Glassy & Surh, 1985; Mirski et al., 1987 Immunoblotting experiments showed that MAb 7.4.1 reacts with three proteins of estimated molecular weights of 186, 169 and 158 kDa (Figure 2 ). No differences were observed between samples tested under reducing and nonreducing conditions. It is possible that the two smaller proteins represent proteolytic breakdown products of the 186 kDa protein. However, this seems unlikely since protease inhibitors were included in the lysis buffer used to prepare cell extracts. A second possibility is that the difference bands may reflect different degrees of glycosylation of a single protein. Finally, it is also possible that MAb 7.4.1 recognises a common epitope on three unrelated proteins. Further investigation is required to determine which of these explanations accounts for the multiplicity of bands observed. An immunoblot performed under identical conditions but incubated with MAb C219 against P-glycoprotein showed a single broad band of estimated molecular weight 168 kDa on membrane preparations from AD cells (Figure 2) .
The ability of MAb 7.4.1 to cross-react with other cell lines was examined by indirect cell ELISA (Figure 3 ). The cell lines tested included human cell lines H69, HT1080, WiDr and 8226/S as well as the Chinese hamster ovary (CHO) cell line Aux B1 and their respective drug-resistant variants, i.e. H69AR (Mirski et al., 1987) , HT1080/DR4 (Slovak et al., 1988) , WiDr/R (Dalton et al., 1988) , 8226/R40 (Dalton et al., 1986 ) and CHRC5 (Ling & Thompson, 1974) . MAb 7.4.1 showed strong reactivity with both the drug-sensitive and -resistant fibrosarcoma cell lines, HT1080 and HT1080/DR4. Both colon carcinoma cell lines were also positive although reactivity was considerably greater on the drug-resistant WiDr/R than its sensitive parent. No reactivity was observed with the myeloma cell lines, 8226/S and 8226/R40, the CHO cell lines, Aux Bi and CHRC5, nor the small cell lung tumour cell lines, H69 Gerlach et al. (1987) and protein concentration determined (Peterson, 1977) . Forty ytg of protein was subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (Laemmli, 1970) (Mierendorf et al., 1987) . For detection' of P-glycoprotein, 120 gg of protein from the membrane fraction of AD cells was electrophoresed and blotted as above and the blot incubated with 125 ng ml-' MAb C219 (Centocor, Malvern, PA) and binding detected as for MAb 7.4.1. 7.4.1 does not cross-react with CHRC5 and 8226/Dox cells, which are known to overexpress P-glycoprotein (Ling & Thompson, 1974; Dalton et al., 1986) . Thirdly, MAb 7.4.1 has significant reactivity with two drug-resistant cell lines, WiDr/R and HT1080/DR4, in which enhanced expression of 1 P-glycoprotein is not detectable (Dalton et al., 1988; Slovak et al., 1988) . WiDr/R is a mitoxantrone-selected drugresistant colon carcinoma cell line which does not exhibit the MDR phenotype, as it is commonly defined (Gerlach et al., 1986b) , since it displays only marginal cross-resistance to the Vinca alkaloids (Dalton et al., 1988) . Nevertheless, the antigen(s) defined by MAb 7.4.1 is overexpressed on this resistant cell line compared to its parent cell line. By contrast, MAb 7.4.1 is only slightly more reactive with drug-resistant fibrosarcoma cell line, HT1080/DR4, compared to its parent cell line, HT1080. One interpretation of these results is that the MAb 7.4.1-defined antigen(s) may be only one of several factors mediating drug resistance in these cell lines. Whether this antibody detects the same set of proteins on the HT1080 and WiDr/R cell lines is currently under investigation. It should be noted that this antigen is not invariably associated with non-P-glycoprotein-mediated drug resistance since it is not found on the MDR small cell lung cancer cell line, H69AR (Mirski et al., 1987 
